FDA Approves Vonvendi von Willebrand factor (recombinant) for Perioperative Management of Bleeding in Adult Patients with von Willebrand Disease

Cambridge, Ma. – April 17, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare disease, today announced the U.S. Food and Drug Administration (FDA) has approved Vonvendi [von Willebrand factor (recombinant)], a...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news

Related Links:

CONCLUSIONSĖ NOACs reduced all-cause mortality in patients with or at risk for CAD or PAD, even though they increased the risk of major bleeding. Future studies regarding the best doses of NOACs are warranted. PMID: 31625706 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
ConclusionsEndoscopic microwave ablation with patients under local anesthesia is a novel, safe, effective, rapid, well-tolerated, outpatient treatment for adults with epistaxis of isolated mucosal bulge lesions, especially those for whom general anesthesia might be risky, those with electrical implants, and those exhibiting contraindications for arterial embolization.ResumoIntroduçãoEpistaxe recorrente é uma condição clínica comum nos ambulatórios de rinologia. Sob visualização endoscópica, tanto o cautério bipolar quanto a pinça monopolar ...
Source: Brazilian Journal of Otorhinolaryngology - Category: ENT & OMF Source Type: research
Authors: Kim SH, Song S, Cho HS, Park CY Abstract A 55-year-old man was admitted to the trauma center after a car accident. Cardiac tamponade, traumatic aortic injury, and hemoperitoneum were diagnosed by ultrasonography. The trauma surgeon, cardiac surgeon, and interventional radiologist discussed the prioritization of interventions. Multi-detector computed tomography was carried out first to determine the severity and extent of the injuries, followed by exploratory sternotomy to repair a left auricle rupture. A damage control laparotomy was then performed to control mesenteric bleeding. Lastly, a descending thora...
Source: Korean Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Korean J Thorac Cardiovasc Surg Source Type: research
Conclusion: Long-term OS and RFS after the surgical resection of primary chest wall sarcoma were clinically acceptable. PMID: 31624714 [PubMed]
Source: Korean Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Korean J Thorac Cardiovasc Surg Source Type: research
Publication date: Available online 19 October 2019Source: Canadian Journal of CardiologyAuthor(s): Ana Paula de Faria, Rodrigo Modolo, Ply Chichareon, Chun-Chin Chang, Norihiro Kogame, Mariusz Tomaniak, Kuniaki Takahashi, Tessa Rademaker-Havinga, Joanna Wykrzykowska, Rob J. de Winter, Rui C. Ferreira, Amanda Sousa, Pedro A. Lemos, Scot Garg, Christian Hamm, Peter Juni, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Yoshinobu OnumaAbstractBackgroundWe evaluated the association of pulse pressure (PP) and different antiplatelet regimes with clinical and safety outcomes in an all-comers percutaneous coronary intervention...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Authors: Buccheri S, Capodanno D, James S, Angiolillo DJ Abstract Introduction: Potent platelet inhibition reduces the risk of thrombotic complications including myocardial infarction and death in patients with acute coronary syndrome (ACS). Targeting different pathways involved in thrombotic processes have synergistic effects and more effectively counteract thrombosis both in the acute and long-term following an ACS. Unavoidably, more potent platelet inhibition increases the risk of bleeding. In light of the adverse prognostic implications associated with bleeding, including increased mortality, safety aspects wit...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Discussion &conclusionThe treatment strategy should be tailored to the individual patient, the clinical presentation, and the rate of progression of the tumor. The natural history of the disease is still poorly understood and there is no uniform treatment form for such tumors.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
In this study, the potential of PF-06741086 to restore thrombin generation in rare disease plasma was explored.Thrombin generation was measured in citrated platelet poor Factor XI (FXI), Factor V (FV), FVII, von Willebrand Factor (vWF) deficient (Type 1, 2A, 2B and 3) congenital donor plasma following the in vitro addition of PF-06741086 (0, 1, 10 or 100 nM) or a human IgG1 antibody; initiated with 1 pM TF and 4 µM phospholipid. FXI, FV, and FVII donors had less than 1% coagulation factor activity. Non-hemophilic plasma from healthy donors alone was also included in the analysis. In FXI deficient plasmas, a concentra...
Source: Blood - Category: Hematology Authors: Tags: 321. Blood Coagulation and Fibrinolytic Factors: Poster II Source Type: research
We report here the case of a BSS patient who presented with persistent thrombocytopenia (31x10(9)/L) and decreased surface expression of GPIb-IX-V on large platelets with anisocytosis. Thorough molecular analyses disclosed two previously unreported GP9 variants, respectively c.230T>A (p.Leu77Gln) and c.255C>A (p.Asn85Lys). Both are likely to modify the conformation of GP-IX interactions with other glycoproteins of the Ib-IX-V complex and thus proper expression of this complex on the membrane of platelets. PMID: 29119855 [PubMed - as supplied by publisher]
Source: Platelets - Category: Hematology Tags: Platelets Source Type: research
Autosomal recessive bleeding disorders (ARBDs) include deficiencies of clotting factors I, II, V, VII, X, XI, XIII, vitamin K dependent clotting factors, combined factor V&VIII, Von Willebrand Disease (vWD) ...
Source: Orphanet Journal of Rare Diseases - Category: Internal Medicine Authors: Source Type: research
More News: Biotechnology | Bleeding | Drugs & Pharmacology | Food and Drug Administration (FDA) | Rare Diseases | von Willebrand Disease